omniture
logo
Search
上海齐鲁锐格医药研发有限公司 Shanghai Qiluruge Pharmaceutical Research And Development Co. Ltd
Media Room

Latest News

rss

Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity

CAMBRIDGE, Mass., March 8, 2024 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a clinical-stag...

2024-03-08 23:24 1543

Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy

* RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phas...

2023-12-08 07:39 1450

Regor Therapeutics Announces Completion of $90 Million Series B Financing

SHANGHAI, Feb. 19, 2021 /PRNewswire/ -- Regor Therapeutics, a clinical stage biotechnology company ...

2021-02-19 08:00 4672